Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

[1]  Edward W Boyer,et al.  Management of opioid analgesic overdose. , 2012, The New England journal of medicine.

[2]  Laxmaiah Manchikanti,et al.  Opioid epidemic in the United States. , 2012, Pain physician.

[3]  J. Brockmöller,et al.  The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. , 2012, Biochemical pharmacology.

[4]  M. Hayden,et al.  More Codeine Fatalities After Tonsillectomy in North American Children , 2012, Pediatrics.

[5]  M. Hayden,et al.  Prediction of Codeine Toxicity in Infants and Their Mothers Using a Novel Combination of Maternal Genetic Markers , 2012, Clinical pharmacology and therapeutics.

[6]  M. Pirmohamed,et al.  Lamotrigine is a substrate for OCT1 in brain endothelial cells. , 2012, Biochemical pharmacology.

[7]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[8]  Tetsuya Terasaki,et al.  Absolute Quantification and Differential Expression of Drug Transporters, Cytochrome P450 Enzymes, and UDP-Glucuronosyltransferases in Cultured Primary Human Hepatocytes , 2012, Drug Metabolism and Disposition.

[9]  K. Giacomini,et al.  Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions , 2011, The Pharmacogenomics Journal.

[10]  J. Lötsch,et al.  Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol , 2011, Clinical pharmacology and therapeutics.

[11]  A. Caraceni,et al.  Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project , 2011, Palliative medicine.

[12]  Y Kumagai,et al.  Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects , 2011, Clinical pharmacology and therapeutics.

[13]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[14]  R. Kaiser,et al.  Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron , 2010, The Pharmacogenomics Journal.

[15]  H. Liou,et al.  Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood‐brain barrier and MPTP‐induced dopaminergic toxicity in rodents , 2010, Journal of neurochemistry.

[16]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[17]  G. Koren,et al.  Codeine, ultrarapid-metabolism genotype, and postoperative death. , 2009, The New England journal of medicine.

[18]  D. Keppler,et al.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.

[19]  A. Doehring,et al.  Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? , 2009, PAIN®.

[20]  B. Carleton,et al.  Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study , 2009, Clinical pharmacology and therapeutics.

[21]  Christel A. S. Bergström,et al.  Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.

[22]  J Kirchheiner,et al.  Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication , 2007, The Pharmacogenomics Journal.

[23]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[24]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[25]  Jukka Corander,et al.  CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure , 2007, Pharmacogenetics and genomics.

[26]  Gideon Koren,et al.  Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother , 2006, The Lancet.

[27]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Dahan,et al.  Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[30]  S. Leucht,et al.  Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. , 2004, Clinical chemistry.

[31]  A. Galetin,et al.  Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[32]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Yuichi Sugiyama,et al.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? , 2002, AAPS PharmSci.

[34]  U. Brinkmann,et al.  Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. , 2002, Pharmacogenetics.

[35]  G. Pasternak,et al.  Strategies to manage the adverse effects of oral morphine: an evidence-based report. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  H. Jung,et al.  Pharmacokinetics of a Sustained‐Release Dosage Form of Clomipramine , 2000, Journal of clinical pharmacology.

[37]  G. Corso,et al.  Fluoxetine Bioequivalence Study: Quantification of Fluoxetine and Norfluoxetine by Liquid Chromatography Coupled to Mass Spectrometry , 1999, Journal of clinical pharmacology.

[38]  R. Moore,et al.  Peak plasma concentrations after oral morphine: a systematic review. , 1998, Journal of pain and symptom management.

[39]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[40]  R. Moore,et al.  Systematic review of factors affecting the ratios of morphine and its major metabolites , 1998, Pain.

[41]  U. Wille,et al.  Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. , 1995, Life sciences.

[42]  E. London,et al.  Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans. , 1993, The Journal of pharmacology and experimental therapeutics.

[43]  J. Hasselström,et al.  Morphine Pharmacokinetics and Metabolism in Humans , 1993, Clinical pharmacokinetics.

[44]  A. Somogyi,et al.  Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. , 1991, British journal of clinical pharmacology.

[45]  M. Kelly,et al.  Clomipramine: A Tricyclic Antidepressant Effective in Obsessive Compulsive Disorder , 1990, DICP : the annals of pharmacotherapy.

[46]  S. Joel,et al.  Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine‐6‐glucuronide , 1990, Clinical pharmacology and therapeutics.

[47]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[48]  W H Oldendorf,et al.  Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection , 1972, Science.

[49]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .

[50]  H. Koepsell,et al.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.

[51]  L. Arendt-Nielsen,et al.  Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects , 1996, European Journal of Clinical Pharmacology.

[52]  K. Kutz.  Pharmacology, toxicology and human pharmacokinetics of tropisetron. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.